<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Beam Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/beam-therapeutics-inc</link>
<description>Latest news and press releases for Beam Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/beam-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354bf378dffbe2df0e54fc.webp</url>
<title>Beam Therapeutics Inc</title>
<link>https://6ix.com/company/beam-therapeutics-inc</link>
</image>
<item>
<title>Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-publication-of-beacon-phase-12-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine-18</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-publication-of-beacon-phase-12-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal-of-medicine-18</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)</description>
</item>
<item>
<title>Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-compelling-updated-clinical-data-from-the-ongoing-phase-12-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-to-support-advancement-to-pivotal-development</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-compelling-updated-clinical-data-from-the-ongoing-phase-12-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-to-support-advancement-to-pivotal-development</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT</description>
</item>
<item>
<title>Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-announces-new-liver-targeted-genetic-disease-program-in-phenylketonuria-pku</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-announces-new-liver-targeted-genetic-disease-program-in-phenylketonuria-pku</guid>
<pubDate>Tue, 24 Feb 2026 12:01:00 GMT</pubDate>
<description>New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics</description>
</item>
<item>
<title>Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-dollar500-million-strategic-financing-facility-with-sixth-street</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-dollar500-million-strategic-financing-facility-with-sixth-street</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with</description>
</item>
<item>
<title>Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-to-host-investor-webcast-for-fourth-quarter-and-year-end-2025-financial-results-and-new-liver-targeted-genetic-disease-program</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-to-host-investor-webcast-for-fourth-quarter-and-year-end-2025-financial-results-and-new-liver-targeted-genetic-disease-program</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-sets-strategic-priorities-its-genetic-disease-and-hematology</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-sets-strategic-priorities-its-genetic-disease-and-hematology</guid>
<pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
<description>Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints</description>
</item>
<item>
<title>Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-updated-data-beacon-phase-1-2-trial-ristoglogene</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-updated-data-beacon-phase-1-2-trial-ristoglogene</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S</description>
</item>
<item>
<title>Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-participate-2025-jefferies-london-healthcare-conference-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-participate-2025-jefferies-london-healthcare-conference-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and</description>
</item>
<item>
<title>Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-present-updated-data-beacon-phase-1-2-trial-beam-101-sickle-cell</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-present-updated-data-beacon-phase-1-2-trial-beam-101-sickle-cell</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-participate-upcoming-september-2025-investor-conferences-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-participate-upcoming-september-2025-investor-conferences-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-rmat</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-rmat</guid>
<pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-second-quarter-110000900</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-reports-second-quarter-110000900</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Exploration Underway in Part A and Enrollment Initiated in Part B; Data from Parts A and B of the Phase 1/2 Trial and Clinical Development Update Expected in Early 2026 Dosing Complete for 30 Sickle Cell Disease Patients and First Adolescent Patient Dosed in BEACON Phase 1/2 T</description>
</item>
<item>
<title>Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-new-data-beacon-phase-1-2-clinical-trial-beam-101</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-new-data-beacon-phase-1-2-clinical-trial-beam-101</guid>
<pubDate>Fri, 13 Jun 2025 04:00:00 GMT</pubDate>
<description>Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%,</description>
</item>
<item>
<title>Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-orphan-drug-designation-granted-beam-101-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-orphan-drug-designation-granted-beam-101-treatment</guid>
<pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-orphan-drug-designation-granted-beam-302-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-orphan-drug-designation-granted-beam-302-treatment</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-highlight-new-data-beam-101-program-sickle-cell-disease-european</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-highlight-new-data-beam-101-program-sickle-cell-disease-european</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of</description>
</item>
<item>
<title>Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-participate-2025-rbc-capital-markets-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-participate-2025-rbc-capital-markets-global-healthcare-conference</guid>
<pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
<item>
<title>Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)</title>
<link>https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-rmat-1</link>
<guid isPermaLink="true">https://6ix.com/company/beam-therapeutics-inc/news/beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-rmat-1</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines</description>
</item>
</channel>
</rss>